Michael Moore Sells 40,232 Shares of Viemed Healthcare (NASDAQ:VMD) Stock

Viemed Healthcare, Inc. (NASDAQ:VMD) President Michael Moore sold 40,232 shares of the business’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $9.21, for a total transaction of $370,536.72. Following the transaction, the president owned 1,650,812 shares in the company, valued at approximately $15,203,978.52. This trade represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Michael Moore also recently made the following trade(s):

• On Friday, March 20th, Michael Moore sold 65,000 shares of Viemed Healthcare stock. The shares were sold at an average price of $8.77, for a total transaction of $570,050.00.
• On Wednesday, March 18th, Michael Moore sold 31,570 shares of Viemed Healthcare stock. The shares were sold at an average price of $9.42, for a total transaction of $297,389.40.

Viemed Healthcare Price Performance

Viemed Healthcare stock opened at $8.71 on Friday. Viemed Healthcare, Inc. has a 52 week low of $5.93 and a 52 week high of $10.06. The company’s 50 day moving average price is $8.30 and its two-hundred day moving average price is $7.37. The stock has a market cap of $336.21 million, a P/E ratio of 23.54 and a beta of 1.23. The company has a quick ratio of 1.06, a current ratio of 1.18 and a debt-to-equity ratio of 0.08.

Viemed Healthcare (NASDAQ:VMD) last released its earnings results on Wednesday, March 4th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.02. The company had revenue of $76.18 million during the quarter, compared to analyst estimates of $77.70 million. Viemed Healthcare had a return on equity of 10.72% and a net margin of 5.53%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Viemed Healthcare in a research report on Monday, December 29th. Zacks Research upgraded shares of Viemed Healthcare to a “hold” rating in a research report on Thursday, January 8th. Finally, Wall Street Zen upgraded shares of Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VMD. Intech Investment Management LLC increased its holdings in Viemed Healthcare by 14.4% in the 2nd quarter. Intech Investment Management LLC now owns 18,612 shares of the company’s stock worth $129,000 after acquiring an additional 2,349 shares during the last quarter. Martingale Asset Management L P lifted its holdings in Viemed Healthcare by 6.0% during the fourth quarter. Martingale Asset Management L P now owns 42,483 shares of the company’s stock valued at $316,000 after purchasing an additional 2,399 shares during the last quarter. Invesco Ltd. lifted its holdings in Viemed Healthcare by 17.1% during the fourth quarter. Invesco Ltd. now owns 21,773 shares of the company’s stock valued at $162,000 after purchasing an additional 3,173 shares during the last quarter. State of Alaska Department of Revenue bought a new position in Viemed Healthcare during the fourth quarter worth about $25,000. Finally, Barclays PLC increased its stake in shares of Viemed Healthcare by 2.7% in the fourth quarter. Barclays PLC now owns 131,759 shares of the company’s stock worth $979,000 after purchasing an additional 3,480 shares in the last quarter. Institutional investors own 74.24% of the company’s stock.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.